Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Cash from Investing Activities (2016 - 2024)

Historic Cash from Investing Activities for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2024 value amounting to -$19000.0.

  • Ernexa Therapeutics' Cash from Investing Activities changed N/A to -$19000.0 in Q3 2024 from the same period last year, while for Dec 2024 it was -$365000.0, marking a year-over-year decrease of 182105.26%. This contributed to the annual value of -$365000.0 for FY2024, which is 182105.26% down from last year.
  • According to the latest figures from Q3 2024, Ernexa Therapeutics' Cash from Investing Activities is -$19000.0.
  • In the past 5 years, Ernexa Therapeutics' Cash from Investing Activities registered a high of $267000.0 during Q1 2021, and its lowest value of -$249000.0 during Q2 2024.
  • For the 5-year period, Ernexa Therapeutics' Cash from Investing Activities averaged around -$16916.7, with its median value being -$20360.0 (2020).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 609057.66% in 2021, then crashed by 11722.85% in 2022.
  • Ernexa Therapeutics' Cash from Investing Activities (Quarter) stood at -$12823.0 in 2020, then soared by 2182.2% to $267000.0 in 2021, then tumbled by 51.69% to $129000.0 in 2022, then tumbled by 114.73% to -$19000.0 in 2023, then changed by 0.0% to -$19000.0 in 2024.
  • Its last three reported values are -$19000.0 in Q3 2024, -$249000.0 for Q2 2024, and -$97000.0 during Q1 2024.